NO962130L - Synergistisk behandling av Parkinsons sykdom - Google Patents

Synergistisk behandling av Parkinsons sykdom

Info

Publication number
NO962130L
NO962130L NO962130A NO962130A NO962130L NO 962130 L NO962130 L NO 962130L NO 962130 A NO962130 A NO 962130A NO 962130 A NO962130 A NO 962130A NO 962130 L NO962130 L NO 962130L
Authority
NO
Norway
Prior art keywords
disease
parkinson
synergistic treatment
disclosed
combination
Prior art date
Application number
NO962130A
Other languages
English (en)
Norwegian (no)
Other versions
NO962130D0 (no
Inventor
Bertrand L Chenard
Frank S Menniti
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO962130D0 publication Critical patent/NO962130D0/no
Publication of NO962130L publication Critical patent/NO962130L/no

Links

Classifications

    • G—PHYSICS
    • G10—MUSICAL INSTRUMENTS; ACOUSTICS
    • G10H—ELECTROPHONIC MUSICAL INSTRUMENTS; INSTRUMENTS IN WHICH THE TONES ARE GENERATED BY ELECTROMECHANICAL MEANS OR ELECTRONIC GENERATORS, OR IN WHICH THE TONES ARE SYNTHESISED FROM A DATA STORE
    • G10H5/00—Instruments in which the tones are generated by means of electronic generators
    • G10H5/10—Instruments in which the tones are generated by means of electronic generators using generation of non-sinusoidal basic tones, e.g. saw-tooth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Multimedia (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
NO962130A 1995-05-26 1996-05-24 Synergistisk behandling av Parkinsons sykdom NO962130L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB1995/000398 WO1996037226A2 (en) 1995-05-26 1995-05-26 Combinations for the treatment of parkinsonism containing selective nmda antagonists
HU9601419A HUP9601419A3 (en) 1995-05-26 1996-05-24 Synergetic pharmaceutical compositions for treating parkinson-disease

Publications (2)

Publication Number Publication Date
NO962130D0 NO962130D0 (no) 1996-05-24
NO962130L true NO962130L (no) 1996-11-27

Family

ID=89994003

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962130A NO962130L (no) 1995-05-26 1996-05-24 Synergistisk behandling av Parkinsons sykdom

Country Status (26)

Country Link
US (1) US6258827B1 (de)
EP (1) EP0828513B1 (de)
JP (1) JPH11505828A (de)
CN (1) CN1159325A (de)
AT (1) ATE258067T1 (de)
AU (1) AU696258B2 (de)
BR (1) BR9602485A (de)
CA (1) CA2219911C (de)
CO (1) CO4700422A1 (de)
CZ (1) CZ283979B6 (de)
DE (1) DE69532482T2 (de)
DK (1) DK0828513T3 (de)
ES (1) ES2211904T3 (de)
FI (1) FI974323A7 (de)
HU (1) HUP9601419A3 (de)
IL (1) IL118328A (de)
MX (1) MX9709112A (de)
NO (1) NO962130L (de)
NZ (1) NZ286656A (de)
PL (1) PL314413A1 (de)
PT (1) PT828513E (de)
RU (1) RU2176145C2 (de)
SG (1) SG45479A1 (de)
TR (1) TR199600436A2 (de)
TW (1) TW470740B (de)
WO (1) WO1996037226A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2321190B (en) * 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
EP1024799A1 (de) * 1997-10-24 2000-08-09 Warner-Lambert Company Verfahren zur behandlung von krankheitsbedingten oder arzneistoff induzierten dyskinesien
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6380205B1 (en) 1999-10-29 2002-04-30 Merck & Co., Inc. 2-cyclohexyl quinazoline NMDA/NR2B antagonists
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
US6489477B1 (en) 1999-10-29 2002-12-03 Merck & Co., Inc. 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
AU1153601A (en) 1999-10-29 2001-05-08 Merck Sharp & Dohme Limited Method to treat pain utilizing benzimidazole NMDA NR2B antagonists
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
EP1186303A3 (de) * 2000-09-06 2003-12-10 Pfizer Products Inc. Ein Neutrophilhemmender Faktor und ein selektive NMDA-NR2B Rezeptor Antagonisten enthaltende Kombinationspräparate zur Behandlung von Schlaganfällen und traumatischen Gehirnschäden
PL364625A1 (en) 2001-02-23 2004-12-13 Merck & Co, Inc. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
US7375136B2 (en) 2001-03-08 2008-05-20 Emory University pH-dependent NMDA receptor antagonists
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
DE10142176A1 (de) * 2001-08-29 2003-03-27 Eucro Europe Contract Res Gmbh Verwendung einer Kombination aus ß-adrenergen Agonisten und NDMA-Antagonisten
US7148236B2 (en) 2002-01-17 2006-12-12 Merck & Co., Inc. Modulators of acetylcholine receptors
US6743921B2 (en) * 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
RU2213565C1 (ru) * 2002-06-24 2003-10-10 Общество с ограниченной ответственностью "Паркинфарм" Способ лечебного воздействия на организм пациента при лечении болезни паркинсона
CA2501348A1 (en) * 2002-10-08 2004-04-22 Allergan, Inc. Treatment of dementia and parkinson's disease
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US7763588B2 (en) * 2003-06-13 2010-07-27 The Salk Institute For Biological Studies Method for increasing cognitive function and neurogenesis
US20070010584A1 (en) * 2003-09-04 2007-01-11 Peroutka Stephen J Compositions and methods for orthostatic intolerance
EP1667630A4 (de) * 2003-09-04 2008-07-23 Univ Texas Verfahren und zusammensetzungen zur prävention und behandlung von erkrankungen der genitalien und harnwege, einschliesslich vorzeitiger wehen und leiomyome
EP1588704A1 (de) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamidderivate zur Behandlung des Restless-Leg-Syndroms und der Suchterkrankungen
US20060240043A1 (en) * 2004-10-08 2006-10-26 Meyerson Laurence R Methods and compositions for treating migraine pain
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
RU2281695C1 (ru) * 2004-12-24 2006-08-20 Дмитрий Владимирович Похабов Способ лечения болезни паркинсона
EP1838705A2 (de) * 2005-01-13 2007-10-03 Neurosearch A/S 3,8-substituierte 8-aza-bicyclo [3.2.1] octanderivate und deren verwendung als monoamin-neurotransmitter-wiederaufnahmeinhibitoren
ATE481096T1 (de) 2005-04-06 2010-10-15 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
US20070118044A1 (en) * 2005-07-18 2007-05-24 Mega Elektroniikka Oy Method and device for identifying; measuring and analyzing abnormal neurological responses
EP1870097A1 (de) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamidederivate zur Behandlung von kognitiven Störungen
RU2324492C1 (ru) * 2006-12-04 2008-05-20 Общество с ограниченной ответственностью "Березовый мир" Средство для профилактики и лечения болезни паркинсона
EA201070077A1 (ru) * 2007-06-29 2010-08-30 Эмори Юниверсити Антагонисты nmda-рецепторов с нейропротективным действием
RU2393860C2 (ru) * 2008-05-30 2010-07-10 Государственное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко Федерального агентства по здравоохранению и социальному развитию" Использование тизанидина в качестве корректора лекарственного паркинсонизма
US8969417B2 (en) * 2008-06-06 2015-03-03 Pharmatwob Ltd. Pharmaceutical compositions for treatment of Parkinsons disease
RU2386458C1 (ru) * 2008-09-04 2010-04-20 Государственное Учреждение Научный Центр Неврологии Российской Академии Медицинских Наук Способ лечения болезни паркинсона
US8648198B2 (en) 2011-01-19 2014-02-11 Cold Spring Harbor Laboratory Phenylethanolamine-based NMDA receptor antagonists
KR20140146217A (ko) * 2012-04-20 2014-12-24 유씨비 파마, 에스.에이. 파킨슨병을 치료하는 방법
DK3116475T3 (da) 2014-03-13 2020-12-07 Neuroderm Ltd Dopa-decarboxylasehæmmersammensætninger
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
HU222726B1 (hu) 1990-02-06 2003-09-29 Pfizer, Inc., Piperidinszármazékok, eljárás elżállításukra és az ezeket tartalmazó gyógyszerkészítmények
EP0584192A1 (de) 1991-04-18 1994-03-02 Pfizer Inc. Prodrug-ester von phenolischen 2-piperidino-1-alkanolen
DE4118740A1 (de) 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson
RU2000114C1 (ru) * 1991-07-18 1993-09-07 Васильев В.Н. Способ Васильева В.Н. лечени заболеваний, св занных с недостаточностью дофаминового обмена

Also Published As

Publication number Publication date
HUP9601419A3 (en) 1998-01-28
CA2219911C (en) 2004-07-27
NO962130D0 (no) 1996-05-24
MX9709112A (es) 1998-02-28
CZ283979B6 (cs) 1998-07-15
ES2211904T3 (es) 2004-07-16
RU2176145C2 (ru) 2001-11-27
SG45479A1 (en) 1998-01-16
ATE258067T1 (de) 2004-02-15
BR9602485A (pt) 1998-04-22
HUP9601419A2 (en) 1997-09-29
CO4700422A1 (es) 1998-12-29
FI974323A0 (fi) 1997-11-25
DE69532482T2 (de) 2004-11-25
PT828513E (pt) 2004-05-31
TR199600436A2 (tr) 1996-12-21
FI974323L (fi) 1997-11-25
JPH11505828A (ja) 1999-05-25
CA2219911A1 (en) 1996-11-28
DK0828513T3 (da) 2004-04-13
PL314413A1 (en) 1996-12-09
CN1159325A (zh) 1997-09-17
WO1996037226A3 (en) 1996-12-27
DE69532482D1 (de) 2004-02-26
EP0828513B1 (de) 2004-01-21
CZ152496A3 (cs) 1998-04-15
IL118328A (en) 2001-06-14
TW470740B (en) 2002-01-01
AU5451996A (en) 1996-12-05
US6258827B1 (en) 2001-07-10
FI974323A7 (fi) 1997-11-25
EP0828513A2 (de) 1998-03-18
HU9601419D0 (en) 1996-07-29
WO1996037226A2 (en) 1996-11-28
NZ286656A (en) 2001-03-30
AU696258B2 (en) 1998-09-03
IL118328A0 (en) 1996-09-12

Similar Documents

Publication Publication Date Title
NO962130L (no) Synergistisk behandling av Parkinsons sykdom
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
EA200801806A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
BG105534A (en) 5ht1 means and method for the treatment of migraine
NZ502804A (en) 1-(N-(2-substituted phenyl)aminoalkyl)-piperazine derivatives
EA199700119A1 (ru) Соединения, оказывающие эффекты на системы, связанные с серотонином
MXPA03010843A (es) Uso de derivados con azetidinona en el tratamiento de enfermedad de alzheimer.
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
CA2204616A1 (en) Ppar gamma antagonists for treating obesity
NO962538L (no) 6-(2-imidazolinylamino)kinoksalin-forbindelser anvendbare som -2-adrenoceptor-agonister
EP1064966A3 (de) Zusammensetzungen von 5HT1-Rezeptor -Antagonisten, Koffein und COX-2 Inhibitoren zur Behandlung von Migräne
JO3446B1 (ar) طريقة لمعالجة الأرق الأولي
NO20005223L (no) Sammensetning for og behandling av inflammatrisk tarmsykdom ved administrering av N-acetylglucosamin i tykktarmen
AU738121B2 (en) Use of 5HT1A receptor antagonists for preventing and/or treating temporal lobe epilepsy
EP1064948A3 (de) Zusammensetzungen von 5HT1-Rezeptor -Antagonisten, Koffein und COX-2 Inhibitoren zur Behandlung von Migräne
MY118944A (en) Synergistic treatment for parkinsonism
MX9604692A (es) Derivados de quinoxalina para el tratamiento de tinnitus.
EP1051994A3 (de) 5HT1-Rezeptor-Agonisten und COX-2 Inhibitoren zur Behandlung von Migräne
PT950053E (pt) Novos derivados de benzoilalquil-1,2,3,6-tetra-hidropiridinas
NO951865L (no) Quinuclidin-derivat som substans-P antagonist
MX9701528A (es) Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer.
DE69625819D1 (de) Die verwendung von ondansetron zur herstellung eines medikamentes zur behandlung von tremor
ITMI920106A1 (it) Composizioni farmaceutiche comprendenti melatonina o un suo derivato-agonista, atte al trattamento dei disordini cerebro-vascolari